Transcriptional activation domains share little sequence homology and generally lack folded structures in the absence of their targets, aspects that have rendered activation domains difficult to characterize. Here, a combination of biochemical and nuclear magnetic resonance experiments demonstrates that the activation domain of the tumor suppressor p53 has an FXX⌽⌽ motif (F, Phe; X, any amino acids; ⌽, hydrophobic residues) that folds into an ␣-helix upon binding to one of its targets, hTAFII31 (a human TFIID TATA box-binding protein-associated factor). MDM2, the cellular attenuator of p53, discriminates the FXX⌽⌽ motif of p53 from those of NF-B p65 and VP16 and specifically inhibits p53 activity. Our studies support the notion that the FXX⌽⌽ sequence is a general ␣-helical recognition motif for hTAFII31 and provide insights into the mechanistic basis for regulation of p53 function.
T
he tumor suppressor p53 plays a pivotal role in maintaining the genomic integrity of the cell by arresting cell growth or initiating apoptosis (1) . One mechanism by which the p53 protein exerts its antiproliferative activity is by inducing the transcription of genes that control cell growth. The ability of p53 to function as a transcription factor depends critically on its two modular domains: an NH 2 -terminal transcriptional activation domain (amino acids 1-42) and a central DNA-binding domain (amino acids 120-290). The DNA-binding domain provides gene specificity by binding to specific DNA sequences, and the activation domain stimulates transcription by interacting with hTAF II 31 and hTAF II 70 (2, 3) in addition to cellular coactivators p300͞CBP (4) (5) (6) (7) . Although mutations in p53 that arise in human cancers cluster in the DNA-binding domain, functional deregulation of the activation domain also is associated with human tumorigenesis (8) . The oncoprotein MDM2, a cellular attenuator of p53 that is overexpressed in certain tumors (9) , and the adenovirus E1B 55-kDa oncoprotein (10) are known to downregulate the p53 protein by masking its activation domain (11) and accelerating its destruction by the ubiquitin-proteosome pathway (12, 13) . The activation domain also plays a central role in responding to cellular signals upon DNA damage. The ATM protein, which is encoded by the gene responsible for the human genetic disorder ataxia telangiectasia (14, 15) , and the DNAactivated protein kinase (16, 17) have been shown to up-regulate the p53 protein upon DNA damage by phosphorylating the activation domain of p53. Therefore, the p53 activation domain acts as a relay switch to control the activation of the p53 protein in response to the status of the cellular genome.
The preponderance of acidic amino acid residues in the p53 activation domain suggests that it is a member of the ''acidic'' class of activators. We previously demonstrated that the VP16 activation domain, a prototypical acidic activator, undergoes an induced transition from random coil to ␣-helix upon binding to hTAF II 31 , with residues along one face of the nascent helix making intermolecular contacts to hTAF II 31 (18) . Identification of these contacting residues suggested that FXX⌽⌽ (F, Phe; X, any amino acids; ⌽, hydrophobic residues) might represent a general recognition motif in acidic activation domains for hTAF II 31 . Here we extend our analysis of the FXX⌽⌽ motif to the p53 activation domain. A combination of biochemical and NMR experiments provides further evidence that the p53 activation domain has a functional FXX⌽⌽ motif that folds up into a short ␣-helix upon binding to hTAF II 31. It is also shown that the MDM2 protein discriminates among FXX⌽⌽ motifs in acidic activators, thus providing a mechanism for the specific inhibition of p53. Comparison between the results on the TAF II 31 interaction motif and the earlier x-ray crystal structure of the p53 activation domain bound to MDM2 (11) allowed identification of Trp 23 and Leu 26 as the primary elements in p53 that enable MDM2 to discriminate the hTAF II 31-binding site in p53 against those in VP16 and p65. This study not only supports the notion that the FXX⌽⌽ sequence is a general ␣-helical recognition motif for hTAF II 31 but also provides insight into the cellular mechanisms controlling transcriptional activation by p53.
Materials and Methods
Proteins. TAF , glutathione S-transferase (GST) fusion proteins, and GAL4 1-94 fusions were expressed and purified as described (18) . The expression plasmid for MDM2 was constructed by cloning a coding DNA fragment generated with PCR into the Escherichia coli vector pLM1. Transformed cells were grown at 37°C to an OD 600 of 0.2 and then at 30°C to an OD 600 of 0.5 in 1 liter of medium. The culture then was induced with 0.4 mM isopropyl ␤-D-thiogalactopyranoside and harvested 5 hr later. The French-pressed bacterial mixture (10 mM Tris⅐HCl, pH 7.4͞400 mM NaCl͞0.1 mM PMSF) was centrifuged at 30,000 ϫ g for 20 min. To the supernatant (10 ml) was added 0.5 ml of 5% polyethyleneimine. After swirling on ice, the sample was centrifuged at 30,000 ϫ g for 20 min. The proteins in the supernatant were precipitated with ammonium sulfate. MDM2 was purified by using SP Sepharose and Q Sepharose columns (Pharmacia) and characterized by electrospray ionization mass spectroscopy.
5 mM perdeuterated DTT, 20 mM perdeuterated Tris-AcOH (pH 6.2), and 10 M EDTA, and then the pH of the solution was adjusted to Ϸ6.0 by adding dilute KOH. The final concentration of p53 9 -25 was determined by UV absorption to be 2.8 mM. NMR experiments were performed in the absence or presence of TAF (300 M) on a Bruker DMX500 spectrometer (Bruker, Billerica, MA) equipped with a z-shielded gradient triple resonance probe. The sequential assignment of the peptide signals was obtained by using a combination of total correlation spectroscopy (TOCSY), double quantum-filtered correlated spectroscopy (DQF-COSY), and nuclear Overhauser effect spectroscopy (NOESY) data sets of a free peptide sample. Sequential d ␣N (i, iϩ1) NOEs were, although weak, observed in the NOESY spectra of the free peptide, which served as a basis for the complete sequential assignment. In the NOESY spectra, 512 free induction decays were recorded at 300 K with mixing times of 200 and 350 ms. The data were processed with the FELIX software (Biosym Technologies, San Diego) with appropriate apodization and zero-filling. We observed large transferred effects as demonstrated by numerous additional NOE cross-peaks in the presence of TAF . This is in good agreement with the relatively weak (fast-exchanging) interaction between the two proteins as revealed by GST pull-down experiments.
Transcription Assays. In vitro transcription assays were performed as described (18) . For the analysis of in vivo transcription, Jurkat cells (Ϸ2 ϫ 10 6 cells) were transfected (10 M DMRIE-C; GIBCO͞BRL) with reporter plasmid pG5IL2SX (2 g) and an expression plasmid of activators (1 g). After 20-hr incubation, aliquots were assayed for secreted alkaline phosphatase activity as described (19) . Cells were harvested and analyzed for DNA binding in gel mobility-shift assays by using a BamHI-HindIII fragment of pG 5 E4 (20) . Similar amounts of DNA-protein complexes were observed in autoradiograms, showing that mutant proteins were expressed to comparable levels. In MDM2 coexpression experiments, 2 g of pG5IL2SX, 0.5 g of each activator expression plasmid, and 0.5-2 g of MDM2 expression plasmid pCHDM1B were used.
Results

FXX⌽⌽ Motifs in p53
and NFB p65. The acidic activation domains of p53 and NFB p65, which have been reported to interact with hTAF II 31 (2, 3, 21) , contain FXX⌽⌽ motifs. Apart from this, there is little sequence similarity between p53, p65, and VP16 activation domains (Fig. 1A) (18) . To evaluate the FXX⌽⌽ sequences in p53 and p65, two short peptides from the activation domains of p53 and p65 that encompass the FXX⌽⌽ sequences (p53 9 -25 and p65 532-548 ) were analyzed for the ability to bind hTAF II 31 and to activate transcription. To assay for hTAF II 31-binding activity, each peptide was fused to GST and analyzed for the ability to pull down the NH 2 -terminal 140-aa fragment of hTAF II 31 (TAF ), this domain being sufficient for activator binding (18) . As shown in Fig. 1B , both p53 9 -25 and p65 532-548 exhibited significant binding activity for TAF . p53 9 -25 and p65 532-548 then were fused to the GAL4 DNA-binding domain, and the resulting proteins were analyzed for the ability to activate transcription in vitro with HeLa nuclear extracts. p53 9 -25 and p65 532-548 activated transcription of the reporter construct containing five GAL4 recognition sites to the same extent as the minimal activation peptide from VP16 (Fig. 1C) . It is noteworthy that the full-length p53 activation domain stimulated transcription more strongly than p53 9 -25 , suggesting the presence of other activation elements in p53 that internally synergize with p53 9 -25 . Nonetheless, mutational studies on p53 have shown that Phe 19 , Leu 22 , and Trp 23 are critical for transcriptional activation by p53 , consistent with the notion that the FXX⌽⌽ motif represents the core segment of the activation domain (24, 25).
These results raised the possibility that FXX⌽⌽ comprises a core activation motif in all three of these activation domains.
The FXX⌽⌽ Motif in p53 Folds Up into an ␣-Helix upon Binding to hTAF II31. To determine the conformation of p53 9 -25 when bound to TAF 1-140 , we performed transferred NOE (TRNOE) NMR experiments. TRNOE relies on rapid exchange between free and bound states of a small ligand interacting weakly with its macromolecular receptor (22) . Under conditions of rapid exchange, negative NOEs conveying conformational information of the bound ligand can be transferred to the resonances of the free ligand. NOEs from the free ligand itself approach zero because of its low molecular weight. Therefore, when the molecular weight of a ligand is low enough, it is possible to detect NOEs primarily from the bound ligand in the presence of substoichemetric amounts of the receptor. Indeed, free p53 9 -25 exhibited few NOEs, as expected for a low-molecular-weight peptide tumbling freely in solution. Although the presence of several weak NOEs between amide protons suggested transient formation of some secondary structure within the FXX⌽⌽ sequence of p53 9 -25 (23) , the overall lack of strong interresidue NOEs indicated the absence of a stably folded structure. Furthermore, the circular dichroism spectrum of the peptide at 27°C exhibited features characteristic of random coil structure (not shown). In the presence of TAF , however, numerous additional NOE cross-peaks appeared, indicative of a large, transferred NOE effect. The appearance of NOE cross-peaks between successive amide protons in the main chain ( Fig. 2A) suggests the formation of an ␣-helix. However, some of the interresidue NOEs in the ␣␤(i, iϩ3) region were difficult to interpret, owing to signal overlap. To circumvent this problem, a shorter peptide, p53 10 -25 , was used for further NMR studies. Its lower molecular weight and fewer signals allowed us to establish the presence of strong ␣␤(i, iϩ3) NOE connectivities in the bound state; these are most characteristic of an ␣-helical structure (Fig. 2B) . The overall pattern of NOEs summarized in has an NOE with a methyl group of Leu 25 rather than its ␤ protons, suggesting, perhaps, a slight deviation from a canonical ␣-helix structure at Leu 25 . As shown in Fig. 2C , the ␣-helix induced in p53 by binding to TAF is shorter than that induced in VP16; the p53 helix has only two turns but still encompasses the FXX⌽⌽ motif, FSDLW. We conclude that an FXX⌽⌽ sequence in the p53 activation domain is a core recognition element for hTAF II 31 that folds up into a short ␣-helix upon binding.
Extensive mutational studies on p53 have identified Phe 19 , Leu 22 , and Trp 23 as critical residues for transcriptional activation by p53 (24, 25) . The projection of residues 18-24 of the p53 activation domain onto a helical wheel reveals that these three residues lie along one face of the helix (Fig. 3A) . Substitution of Phe 19 and Trp 23 with Ala greatly decreased hTAF II 31 binding (Fig. 3B ) and transcriptional activation in transiently transfected cells (Fig. 3C) , despite the fact that these substitutions stabilize ␣-helical structure. Thus, it seems likely that these three residues make direct contacts with chemically complementary residues of hTAF II 31.
Helix Disruption Impairs TAF Binding and Transcriptional Activation.
The significance of ␣-helix formation for transcriptional activation by p53 was examined through the effects of helix disruption on interaction with TAF 1-140 in vitro and transcriptional activation in vivo. To disrupt the ␣-helix formation, Asp 21 at the third position of the FXX⌽⌽ motif in the p53 activation domain was substituted with helix-breaking Pro. Asp 21 was deemed suitable for the analysis because a helical wheel suggested that Asp 21 is located on the other side of the helix from the interface with hTAF II 31 and because substitution of Asp 21 with Ala had no significant effect on TAF binding and transcriptional activation (Fig. 4) . In contrast, substitution with Pro greatly impaired TAF binding and abolished transcriptional activation in transfected cells (Fig. 4) . The mutant proteins were expressed in transfected cells at equal levels as demonstrated by gel mobility-shift analyses (Fig. 4B) . Therefore, the loss of function in the Asp 21 -to-Pro mutant can be considered because of disruption of the helical structure that is required for the FXX⌽⌽ motif of p53 to interact with hTAF II 31.
MDM2 Discriminates Among FXX⌽⌽ Motifs.
The short ␣-helix that is induced upon binding to TAF is almost identical to the one revealed in the crystal structure of p53 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] bound to MDM2 (11) . This observation indicates that the interaction between p53 and MDM2 parallels that between p53 and hTAF II 31 and supports the notion that MDM2 inhibits the p53 function by tightly masking the FXX⌽⌽ sequence in the p53 activation domain. Because the activation domains of p65 and VP16 share FXX⌽⌽ sequences that appear to interact with hTAF II 31, we were interested in testing whether MDM2 has affinity for these activators as well. As shown in Fig. 5A , MDM2 3-109 binds only the p53 activation domain. Thus, MDM2 discriminates the hTAF II 31 binding motif of p53 from those of VP16 and p65. Fig.  1 A) . We therefore reasoned that these two residues, Leu 26 and Trp 23 , might be responsible for the discrimination. To assess this possibility, mutants of the p53 activation domain were constructed and analyzed for the ability to bind TAF 1-140 and MDM2 (Fig. 5B) . Substitution of Trp 23 with Leu, which resulted in retention of a FXX⌽⌽ sequence, greatly decreased MDM2 binding only and had no effect on TAF binding. Removal of Leu 26 significantly reduced MDM2 binding but had no effect on TAF binding ( Fig. 5B ; compare p53 9 -25 and p53 9 -26 ). These data indicated that Trp 23 and Leu 26 are the primary elements that enable MDM2 to discriminate the hTAF II 31-binding site in p53 against those in VP16 and p65.
We next asked whether the in vitro specificity of MDM2 could be recapitulated in transiently transfected cells (Fig. 5C) . The wild-type p53 activation domain fused to the GAL4 DNAbinding domain activated transcription of a reporter gene that was controlled by five GAL4 sites, and its transcriptional activation was greatly inhibited by MDM2 coexpression as reported previously (26) . In contrast, MDM2 coexpression had little effects on transcriptional activation by the activation domains of VP16 and p65. The p53 mutant in which Trp 23 was substituted by Leu still activated transcription, but its transcriptional activation was not influenced significantly by MDM2 coexpression. These results are in good agreement with the in vitro results and with the notion that MDM2 discriminates among FXX⌽⌽ motifs of hTAF II 31-dependent activators in the cells. This precise recognition permits MDM2 to specifically control the p53 protein in the presence of other hTAF II 31-dependent activators.
Although the Trp
23
-Leu mutant bound TAF 1-140 as tightly as the wild type in GST pull-down assays, its ability to activate transcription of the reporter gene in transfected cells was evidently less than that of the wild type. Presumably, the difference in affinity to TAF that was caused by the mutation is modest and undetectable in our GST pull-down assays. It is not clear how much of an affinity change is needed to clearly modulate the intensity of TAF 1-140 bands on SDS͞PAGE gels.
Discussion
Motifs in Transcriptional Activation Domains. Transcriptional activation domains share little sequence homology except a preponderance of particular amino acids (27) . This low homology of activators, which presumably translates into a low affinity for their target proteins, has rendered activation domains elusive. Our results indicate that an FXX⌽⌽ sequence in the p53 activation domain is a short ␣-helical motif that is recognized by hTAF II 31. It is also shown that a short peptide from the p65 activation domain that encompasses an FXX⌽⌽ sequence binds hTAF II 31 and activates transcription. These results, together with those of the VP16 activation domain (18) , strengthen the notion that the FXX⌽⌽ sequence is a general recognition element for hTAF II 31 and may be more generally a signature for acidic activators that interact with hTAF II 31.
Inspection of amino acid sequences of acidic activators identified potential FXX⌽⌽ motifs in a number of acidic activation domains including those of NFAT and BRCA1. Notably, a point mutation of the FXX⌽⌽ sequence of BRCA1 is associated with a preposition to breast and ovarian cancers and disrupts transcriptional activation by BRCA1 (28, 29 (36) , and the interactions of coactivators SRC-1 and GRIP-1 with liganded nuclear receptors also are mediated by an ␣-helical LXXLL sequence (37) (38) (39) . We favor the view that eukaryotic cells have evolved a transcriptional activation mechanism wherein protein-protein interactions within the preinitiation complex are mediated through such short amphipathic helical motifs that resemble each other. This may be a strategy for building dynamic and flexible transcriptional regulatory complexes that are required for specific and steep responses. Because it is now evident that TAFs are not the sole targets for activation domains (40) , the FXX⌽⌽ motif must be just one of many interaction motifs in activation domains. Further identification of these motifs should be helpful for the full understanding of transcriptional activation domains and the dissection of complicated transcriptional regulation.
Insights into Regulation of the p53 Activation Domain. p53 activates transcription of the mdm2 gene whereas its protein product MDM2 suppresses p53 activity (1) . This creates an autoregulatory feedback loop in which both the activity of p53 and the expression of MDM2 are coregulated. Our results suggest that MDM2 inhibits p53 function by tightly masking the FXX⌽⌽ sequence of p53, which otherwise binds hTAF II 31 and activates transcription. Whereas the FXX⌽⌽ motifs in p65 and VP16 have no detectable affinity to MDM2, all three core domains containing FXX⌽⌽ motifs bind equally well to TAF . This promiscuity in binding to TAF but discrimination in binding to MDM2 enables all of the core domains to activate transcription yet only p53 to be inhibited by MDM2, all through interactions near a common peptide segment. Substitution of Trp 23 with Leu in the p53 activation domain, which retains the FXX⌽⌽ sequence, abolished only MDM2 binding and had no effect on TAF binding, indicating that Trp 23 is a major determinant for differential recognition by MDM2. It may be possible to develop indole-based small molecules that inhibit MDM2 but not hTAF II 31 .
It has been reported that p300͞CBP proteins interact with the p53 activation domain and potentiate the transcriptional activity of p53 (5-7). The p300͞CBP interaction region appears to overlap with those of hTAF II 31 and MDM2, because a double point mutation of Leu 22 and Trp 23 abolishes binding with CBP (5) . The involvement of the FXX⌽⌽ sequence of p53 in these multiple interactions suggests competitive binding of hTAF II 31, p300͞CBP , and MDM2 to tetrameric p53. This situation has been complicated by the recent finding that hTAF II 31 is present in the p300͞CBP-associated factor (PCAF)-containing complex (41) . Because PCAF interacts with p300͞CBP, PCAF can be recruited to the promoter by binding to either hTAF II 31 or p300͞CBP. PCAF is a histone acetyltransferase that plays a role in regulation of transcription, cell cycle progression, and differentiation. Recruitment of this important acetylase to p53-responsive promoters may be ensured by binding of the p53 activation domain to hTAF II 31 and p300͞CBP.
The p53 activation domain is also regulated by DNAdependent protein kinase (DNA-PK) and ATM kinase, which phosphorylate Ser 15 of p53 in response to DNA damage (14, 15, 17) . Ser 15 of p53 is located four residues N-terminal to the FXX⌽⌽ motif, and the phosphorylation indeed disrupts the interaction with MDM2 (16) . Interestingly, the ability of p53 to activate transcription is not affected by phosphorylation at Ser 15 (16) , suggesting that the phosphorylation at Ser 15 does not interfere with the interactions with TAFs and p300͞CBP (42) . Although the association sites of hTAF II 31, p300͞CBP, and MDM2 are centered around the FXX⌽⌽ motif, it seems clear that all these partially use distinct interaction modes for this ␣-helical module.
The FXX⌽⌽ sequence and its vicinity in the p53 activation domain functions as a small control unit integrating proteinprotein interactions and posttranslational modification. Such a complex interplay of posttranslational modification and multiple protein-protein interactions offers a mechanism for dynamic control of responses.
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